$0.15
+0.01 (+3.57%)
Open$0.15
Previous Close$0.14
Day High$0.15
Day Low$0.15
52W High$3.09
52W Low$0.05
Volume—
Avg Volume48.1K
Market Cap2.98M
P/E Ratio—
EPS$-2.81
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+27,575.9% upside
Current
$0.15
$0.15
Target
$40.13
$40.13
$29.11
$40.13 avg
$50.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.23M | 38.94M | 9.51M |
| Net Income | -52,587,129 | -48,215,582 | 434.3K |
| Profit Margin | -137.6% | -130.7% | 4.6% |
| EBITDA | -52,539,868 | -50,848,486 | 716.5K |
| Free Cash Flow | — | — | 350.1K |
| Rev Growth | -1.8% | -1.8% | +3.9% |
| Debt/Equity | 9.93 | 9.93 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |